GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » EV-to-FCF

Calidi Biotherapeutics (Calidi Biotherapeutics) EV-to-FCF : -6.00 (As of Jun. 08, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Calidi Biotherapeutics's Enterprise Value is $23.02 Mil. Calidi Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.84 Mil. Therefore, Calidi Biotherapeutics's EV-to-FCF for today is -6.00.

The historical rank and industry rank for Calidi Biotherapeutics's EV-to-FCF or its related term are showing as below:

CLDI' s EV-to-FCF Range Over the Past 10 Years
Min: -53.98   Med: -14.85   Max: -3.58
Current: -6

During the past 4 years, the highest EV-to-FCF of Calidi Biotherapeutics was -3.58. The lowest was -53.98. And the median was -14.85.

CLDI's EV-to-FCF is ranked worse than
100% of 382 companies
in the Biotechnology industry
Industry Median: 8.405 vs CLDI: -6.00

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-08), Calidi Biotherapeutics's stock price is $0.193. Calidi Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.572. Therefore, Calidi Biotherapeutics's PE Ratio for today is At Loss.


Calidi Biotherapeutics EV-to-FCF Historical Data

The historical data trend for Calidi Biotherapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics EV-to-FCF Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - - -2.14

Calidi Biotherapeutics Quarterly Data
Dec20 Sep21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -36.20 -2.14 -8.02

Competitive Comparison of Calidi Biotherapeutics's EV-to-FCF

For the Biotechnology subindustry, Calidi Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calidi Biotherapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Calidi Biotherapeutics's EV-to-FCF falls into.



Calidi Biotherapeutics EV-to-FCF Calculation

Calidi Biotherapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=23.023/-3.836
=-6.00

Calidi Biotherapeutics's current Enterprise Value is $23.02 Mil.
Calidi Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calidi Biotherapeutics  (AMEX:CLDI) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Calidi Biotherapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.193/-0.572
=At Loss

Calidi Biotherapeutics's share price for today is $0.193.
Calidi Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.572.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Calidi Biotherapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines